en 
Deutsch 
Española 
Italiano 
Français 
Polski 
Nederlands 
Svenska (Sverige) 
Czech (Čeština) 
CJC-1295 DAC (Tetrasubstituted 30-Amino Acid Peptide Hormone)
• CAS number: 446262-90-4
• Molecular Weight: 3367.95 g/mol
• Formula: C152H252N44O42
CJC-1295 DAC by DEUS MEDICAL®
CJC-1295 DAC (Tetrasubstituted 30-Amino Acid Peptide Hormone)
Overview
CJC-1295 DAC (Tetrasubstituted 30-Amino Acid Peptide Hormone) is a growth hormone-releasing hormone analog useful in the treatment of growth hormone-deficient adults and children with impaired linear growth. it can also be useful in the treatment of turner syndrome and wasting. It is manufactured as CJC-1295 DAC (Tetrasubstituted 30-Amino Acid Peptide Hormone) 2mg/vial injections which contain Tetrasubstituted 30-Amino Acid Peptide Hormone 2mg and excipients.
CJC-1295 DAC (Tetrasubstituted 30-Amino Acid Peptide Hormone) Mechanism of Action
As a GHRH analogue, CJC-1295 DAC acts on the pituitary gland to stimulate the release of growth hormone. When linked with the Drug Affinity Complex (DAC) It has a half-life of 5 - 8 days which gives it a major advantage over GHRH itself with a half-life of 7 minutes. This means frequent injections are unnecessary. An added benefit is the ability of CJC-1295 DAC to promote deep sleep and memory retention.
CJC-1295 DAC (Tetrasubstituted 30-Amino Acid Peptide Hormone) Dosage
Twice weekly intramuscular Injection.
CJC-1295 DAC Side effects
Fluid retention, weakness, itching, tingling sensation, insulin resistance.
CJC-1295 DAC Interaction
Insulin.
✓ Tetrasubstituted 30-Amino Acid Peptide Hormone . . . 2mg
✓ Excipients . . . . . . . . . . . . . . . . . . . . . q.s
BECOME A PARTNER
We are offering a diverse range of pharmaceutical products, which are available only from an authorized resellers. Our highly-regarded partners are comprised of industry experts who share our values and commitment. Our goal is to strengthen our network of prestigious professionals who strive to deliver great quality products.
We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.